AXDX has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
AXDX has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
FCF Yield % is calculated as Free Cash Flow divided by Market Capitalization. It is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.
As of today, Accelerate Diagnostics's Trailing 12-Month Free Cash Flow is $-24.70 Mil, and Market Cap is $14.52 Mil. Therefore, Accelerate Diagnostics's FCF Yield % for today is -170.08%.
The historical rank and industry rank for Accelerate Diagnostics's FCF Yield % or its related term are showing as below:
During the past 13 years, the highest FCF Yield % of Accelerate Diagnostics was -2.03%. The lowest was -297.74%. And the median was -8.74%.
Accelerate Diagnostics's FCF Margin % for the quarter that ended in Dec. 2024 was -179.97%.
The historical data trend for Accelerate Diagnostics's FCF Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Accelerate Diagnostics Annual Data | |||||||||||||||||||||
Trend | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | Dec24 | |||||||||||
FCF Yield % | Get a 7-Day Free Trial |
![]() |
![]() |
-11.85 | -13.57 | -71.61 | -72.19 | -82.20 |
Accelerate Diagnostics Quarterly Data | ||||||||||||||||||||
Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | Jun24 | Sep24 | Dec24 | |
FCF Yield % | Get a 7-Day Free Trial |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
-55.08 | -166.07 | -109.51 | -29.00 | -67.45 |
For the Medical Devices subindustry, Accelerate Diagnostics's FCF Yield %, along with its competitors' market caps and FCF Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Medical Devices & Instruments industry and Healthcare sector, Accelerate Diagnostics's FCF Yield % distribution charts can be found below:
* The bar in red indicates where Accelerate Diagnostics's FCF Yield % falls into.
FCF Yield % is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.
Accelerate Diagnostics's FCF Yield % for the fiscal year that ended in Dec. 2024 is calculated as
FCF Yield % | = | Free Cash Flow | / | Market Cap |
= | -24.703 | / | 30.0528 | |
= | -82.20% |
Accelerate Diagnostics's annualized FCF Yield % for the quarter that ended in Dec. 2024 is calculated as
FCF Yield % | = | Free Cash Flow | * | Annualized Factor | / | Market Cap |
= | -5.068 | * | 4 | / | 30.0528 | |
= | -67.45% |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Accelerate Diagnostics FCF Yield % Explanation
Similar to Earnings Yield %, FCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high free cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.
Thank you for viewing the detailed overview of Accelerate Diagnostics's FCF Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.
David Patience | officer: Chief Financial Officer | C/O ACCELERATE DIAGNOSTICS, INC., 3950 S. COUNTRY CLUB ROAD, SUITE 240, TUCSON AZ 85714 |
John Patience | director, 10 percent owner | 28161 N. KEITH DRIVE, LAKE FOREST IL 60045 |
Jack W Schuler | director, 10 percent owner | 100 N. FIELD DRIVE, SUITE 360, LAKE FOREST IL 60045 |
Larry Michael Mertz | officer: Chief Technology Officer | 3950 S. COUNTRY CLUB ROAD, TUCSON AZ 85714 |
Jack Phillips | director, officer: PRESIDENT AND CEO | 11731 YALE DR, CARMEL IN 46032 |
Marran H. Ogilvie | director | 599 LEXINGTON AVENUE, NEW YORK NY 10022 |
Jennifer Regan | director | C/O ACCELERATE DIAGNOSTICS, INC., 3950 S. COUNTRY CLUB ROAD, SUITE 470, TUCSON AZ 85714 |
Mark S. Black | director | 3950 S. COUNTRY CLUB ROAD, SUITE 470, TUCSON AZ 85714 |
Steven Reichling | officer: CFO | 7000 NORTH BROADWAY, BUILDING 3-307, DENVER CO 80221 |
Ron Price | officer: SVP & HEAD OF COM OPS AMERICAS | 3950 SOUTH COUNTRY CLUB ROAD, SUITE 470, TUCSON AZ 85714 |
Wayne Burris | director | 3451 PLANO PARKWAY, LEWISVILLE TX 75056 |
Hany Massarany | director | 1910 INNOVATION PARK DR, TUCSON AZ 85737 |
Mark C Miller | director | C/O STERICYCLE INC., 28161 N KEITH DRIVE, LAKE FOREST IL 60045 |
Louise Francesconi | director | 870 WINTER STREET, WALTHAM MA 02451 |
Charles M Watts | director | 3950 SOUTH COUNTRY CLUB, SUITE 470, TUCSON AZ 85714 |
From GuruFocus
By GuruFocus Research • 02-06-2024
By GuruFocus Research • 02-06-2024
By PRNewswire • 05-02-2024
By PRNewswire • 03-21-2025
By GuruFocus Research • 02-06-2024
By PRNewswire • 01-10-2025
By GuruFocus News • 02-15-2025
By GuruFocus News • 11-08-2024
By GuruFocus News • 11-08-2024
By GuruFocus News • 10-09-2024
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.